
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideo
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Don’t miss our latest news! Sign up today for our free newsletter.
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Achillion's experimental nucleoside drug elvucitabine remains at therapeutic levels in the body for so long that it might be possible to be dosed just once weekly, according to company researchers. Study data presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy showed that when elvucitabine treatment was halted, blood-based concentrations of the drug remained three times higher than the level needed to inhibit viral replication by 50%'even 28 days after stopping the drug. AIDS experts say that while Achillion will continue developing the drug as a once-daily treatment, the new trial data will likely spur additional research into less-frequent dosing, including a possible once-weekly pill.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Don’t miss our latest news! Sign up today for our free newsletter.
Plus: Featured Video
Latest Stories
‘Kokomo City’ Gives a Searing Look Into Lives of Black Trans Sex Workers
August 18 2023 12:40 PM